MigraineMind research summary

TRPM8 channel blockers as a potential new pharmacological class for the treatment of migraine.

Expert Rev Clin Pharmacol | 2026

Clinical trial
AuthorsPellesi L, Chiarugi A, Kupferman J, Crutchlow M, Martelletti P
JournalExpert Rev Clin Pharmacol
Publication year2026
PubMed ID43046674

Summary

Recent migraine treatments have improved, especially with CGRP-targeting drugs. However, some patients still struggle with existing options. Triptans and gepants do not work for everyone. Researchers are exploring TRPM8, a specific channel in the body, as a new treatment target. This channel is involved in how migraines develop. Evidence from genetics and studies supports its role in migraines. The paper reviews various TRPM8-interacting compounds currently being tested. It discusses their effects, how they work, and their potential benefits. Researchers searched databases for studies and clinical trials related to TRPM8 and migraines. They also looked at recent conference findings. This research suggests that blocking TRPM8 could offer a new way to treat migraines effectively. Overall, this could lead to better options for patients who do not respond to current therapies. Clinical relevance: This research indicates that TRPM8 channel blockers may provide new treatment options for migraine patients who do not respond to existing medications.

Original research

Read the original publication and review its full methods and findings on PubMed.

MigraineMind is an educational resource designed to complement—not replace—the original scientific literature or clinical judgement. This page is an AI-generated summary of the available paper information and may contain errors. Please consult the original publication.